Varicella zoster virus - 07/09/11
Abstract |
Because of its ability to produce two clinically distinct disease entities (chickenpox and shingles), varicella zoster virus (VZV) is an unusual etiologic agent. Although in the past viral exanthems were mostly only of academic interest to the practitioner, the development of antiviral agents and the newly approved varicella (OKA) vaccine have increased the clinical significance. Also, with the increasing seroprevalence of HIV infection, more patients will be stricken with zoster (at a younger age) and disseminated varicella. In this review, the history, incidence, pathogenesis, clinical manifestations, and treatment options (of VZV infection and postherpetic neuralgia) will be discussed. (J Am Acad Dermatol 1999;41:1-14.) Learning Objective: At the completion of this learning activity, participants should be able to discuss the history, incidence, pathogenesis, clinical manifestations, and treatment options for both VZV infection and PHN.
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Stephen K. Tyring, MD, PhD, Department of Dermatology, University of Texas Medical Branch, Galveston, TX 77555-1070. E-mail: tyring@flash.net. |
|
0190-9622/99/$8.00 + 0 16/2/98761 |
Vol 41 - N° 1
P. 1-16 - juillet 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?